Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest autoimmune treatment options. These biosimilars to Stelara have received official clearance on October 17, heralding a new era of affordable treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z9nY6Mk
via IFTTT